The CALMA Clinical Trial is a Phase 2, FDA-registered research study for people living with Alzheimer’s disease who experience agitation. Agitation can include restlessness, pacing, repeated questions, irritability, verbal outbursts, or aggression. These symptoms are very challenging for both patients and caregivers. The purpose of CALMA is to study an investigational medicine, IGC-AD1, an oral liquid solution that contains tetrahydrocannabinol (THC) and melatonin. In earlier research, this medicine was shown to be safe and well-tolerated. Now, we are testing whether it can help reduce agitation symptoms and continue researching safety and tolerability.